US 11,999,802 B2
Compositions and methods for selective protein degradation
James E. Bradner, Weston, MA (US); Andrei Golosov, Cambridge, MA (US); Carleton Proctor Goold, Brighton, MA (US); Carla Patricia Pinto Guimaraes, Boston, MA (US); Marc Horst Peter Hild, Wellesley, MA (US); Gregory Motz, Quincy, MA (US); Nathan Thomas Ross, Cambridge, MA (US); Jonathan M. Solomon, Somerville, MA (US); Rohan Eric John Beckwith, Maynard, MA (US); and Seth Carbonneau, Roxbury, MA (US)
Assigned to Novartis AG, Basel (CH)
Appl. No. 16/757,026
Filed by Novartis AG, Basel (CH)
PCT Filed Oct. 18, 2018, PCT No. PCT/US2018/056472
§ 371(c)(1), (2) Date Apr. 17, 2020,
PCT Pub. No. WO2019/079569, PCT Pub. Date Apr. 25, 2019.
Claims priority of provisional application 62/574,188, filed on Oct. 18, 2017.
Prior Publication US 2020/0339704 A1, Oct. 29, 2020
Int. Cl. C07K 19/00 (2006.01); A61K 31/4545 (2006.01); A61K 31/46 (2006.01); A61K 35/12 (2015.01); C07D 209/48 (2006.01); C07D 213/81 (2006.01); C07D 401/14 (2006.01); C07D 451/02 (2006.01); C07K 14/435 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12N 9/06 (2006.01); C12N 15/63 (2006.01); C12N 15/86 (2006.01); G01N 33/68 (2006.01)
CPC C07K 19/00 (2013.01) [A61K 31/4545 (2013.01); A61K 31/46 (2013.01); A61K 35/12 (2013.01); C07D 209/48 (2013.01); C07D 213/81 (2013.01); C07D 401/14 (2013.01); C07D 451/02 (2013.01); C07K 14/435 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 16/2815 (2013.01); C07K 16/2863 (2013.01); C07K 16/2875 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C12N 9/003 (2013.01); C12N 15/63 (2013.01); C12N 15/86 (2013.01); C12Y 105/01003 (2013.01); G01N 33/6803 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/20 (2013.01); C07K 2319/35 (2013.01); C07K 2319/81 (2013.01); C07K 2319/95 (2013.01); C12N 2740/15043 (2013.01)] 33 Claims
 
1. A fusion polypeptide comprising:
(i) a CRBN (cereblon)-binding polypeptide, and
(ii) a chimeric antigen receptor (CAR) that comprises, in a N-terminal to C-terminal direction, an antigen binding domain, a transmembrane domain, and one or more intracellular signaling domains, wherein the CRBN-binding polypeptide comprises the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 1.